Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310771) titled 'Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fujian Cancer Hospital
Condition:
Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)
Intervention:
Drug: Sintilimab combined with chemotherapy and nimotuzumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 10, 2026
Target Sample Size: 23
To know more, visit...